|Application:||Gene expression microarray analysis|
|Number of samples:||24|
|Release date:||Nov 29 2015|
|Last update date:||Oct 22 2018|
|Diseases:||Graft vs Host Disease|
|Dataset link||AURKA Expression in allogeneic HCT-recipients|
Samples were obtained from patients enrolled in hematopoietic stem cell transplant (HCT) clinical trials performed at Emory University and the University of Minnesota, with and without GVHD. Patients from Emory University were enrolled on two contemporaneous IRB-approved clinical trials: (1) The Bone Marrow Immune Monitoring Protocol and (2) The Abatacept Feasibility Study. The patients from the University of Minnesota were enrolled on an immune monitoring protocol approved by the University of Minnesota IRB. Samples from patients with acute GVHD were identified and then control samples were selected that were matched for sample collection day, preparative regimen intensity, disease, stem cell source, and GVHD prophylaxis.